Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Pakistan
ACTRN12620000426987Phase 4Completed
- Sponsor
- Ministry of National Health Services Regulations and Coordination
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemether + lumefantrine in malaria and Falciparum malaria (PF), sponsored by Ministry of National Health Services Regulations and Coordination. Primary endpoint: Percent of treatment failures. Started Sep 2019; status: completed.
02
Drugs
artemether + lumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12620000426987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000426987.